Literature DB >> 2413942

Effects of selective channel blocking agents on contractions and action potentials in K+-depolarized guinea-pig atria.

J Brown, R J Marshall, E Winslow.   

Abstract

Contractions and transmembrane action potentials were induced by 1 microM isoprenaline in K+-depolarized guinea-pig left atria driven at 0.5 Hz. The stability of these responses was significantly increased by doubling the extracellular glucose concentration to 22 mM. Action potential overshoot increased by 28 mV per ten fold increase in extracellular calcium concentration suggesting that the inward current in this preparation is carried by Ca2+. In depolarized driven preparations, nanomolar concentrations of nifedipine and nisoldipine reduced contractility, maximum rate of depolarization (dV/dt max) and action potential height, whereas the fast channel blocking agents tetrodotoxin and mexiletine (in micromolar concentrations) produced little change. Nifedipine also rendered spontaneously beating depolarized right atrial preparations quiescent. In concentrations which reduced dV/dt of normal action potentials, the sodium channel blocking agents quinidine and Org 6001 reduced the amplitude of contractions and reduced the maximum rate of phase 0 depolarization (dV/dt) of action potentials in depolarized tissue. These actions were reversed by Ca2+ and suggest calcium antagonistic activity. However action potential height was not reduced. Like bepridil, both drugs also reduced the frequency of spontaneous contractions in depolarized right atrial preparations. Unlike Org 6001, quinidine failed to produce a shift in calcium log dose-response curves in driven depolarized preparations and induced positive inotropy in the presence of functional sodium channels. Bepridil inhibited contractions in depolarized atria in the absence of a reduction in dV/dt suggesting that any calcium antagonistic action in atrial tissue is mainly located at an intracellular site. In conclusion, action potentials elicited by isoprenaline in potassium-depolarized atria bathed in high glucose appear to be Ca2+ mediated. In concentrations which inhibit the inward Na+ current, both quinidine and Org 6001 exhibit calcium channel blocking properties.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413942      PMCID: PMC1916864          DOI: 10.1111/j.1476-5381.1985.tb09429.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Actions of some antiarrhythmic agents on heart sarcolemma.

Authors:  N S Dhalla; J A Harrow; M B Anand
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

2.  Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium.

Authors:  M Kohlhardt; A Fleckenstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-07       Impact factor: 3.000

Review 3.  Classification of antidysrhythmic drugs.

Authors:  E M Vaughan Williams
Journal:  Pharmacol Ther B       Date:  1975

4.  [BAY a 1040--a highly potent Ca ++ -antagonistic inhibitor of electro-mechanical coupling processes in mammalian myocardium].

Authors:  A Fleckenstein; H Tritthart; H J Döring; K Y Byon
Journal:  Arzneimittelforschung       Date:  1972-01

5.  The demonstration of energy dependence of the isoproterenol-induced transcellular Ca2+ current in isolated perfused guinea pig hearts--an explanation for mechanical failure of ischemic myocardium.

Authors:  J A Schneider; N Sperelakis
Journal:  J Surg Res       Date:  1974-04       Impact factor: 2.192

6.  Some effects of caffeine and quinidine on sarcoplasmic reticulum of skeletal and cardiac muscle.

Authors:  W R Thorpe
Journal:  Can J Physiol Pharmacol       Date:  1973-07       Impact factor: 2.273

7.  Blockade of myocardial slow channels by bepridil (CERM-1978).

Authors:  S Vogel; R Crampton; N Sperelakis
Journal:  J Pharmacol Exp Ther       Date:  1979-09       Impact factor: 4.030

8.  The effect of quinidine on membrane electrical activity in frog auricular fibres studied by current and voltage clamp.

Authors:  P Ducouret
Journal:  Br J Pharmacol       Date:  1976-06       Impact factor: 8.739

9.  Effects of bepridil on the electrophysiological properties of guinea-pig ventricular muscles.

Authors:  T Anno; T Furuta; M Itho; I Kodama; J Toyama; K Yamada
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

10.  The effect of quinidine on calcium accumulation by isolated sarcoplasmic reticulum of skeletal and cardiac muscle.

Authors:  F Fuchs; E W Gertz; F N Briggs
Journal:  J Gen Physiol       Date:  1968-12       Impact factor: 4.086

View more
  5 in total

Review 1.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

2.  Comparative effects of bepridil, its quaternary derivative CERM 11888 and verapamil on caffeine-induced contracture in ferret hearts.

Authors:  J Leboeuf; C Leoty; J C Lamar; R Massingham
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

3.  Comparative antiarrhythmic and electrophysiological effects of drugs known to inhibit calmodulin (TFP, W7 and bepridil).

Authors:  E Barron; R J Marshall; M Martorana; E Winslow
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

Review 4.  Bepridil: a pharmacological reappraisal of its potential beneficial effects in angina and tissue protection following ischemia.

Authors:  R Massingham; P A Van Zwieten
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

5.  Frequency-Dependent Multi-Well Cardiotoxicity Screening Enabled by Optogenetic Stimulation.

Authors:  Susanne Rehnelt; Daniela Malan; Krisztina Juhasz; Benjamin Wolters; Leo Doerr; Matthias Beckler; Ralf Kettenhofen; Heribert Bohlen; Tobias Bruegmann; Philipp Sasse
Journal:  Int J Mol Sci       Date:  2017-12-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.